web logo
  • Therapies
    • DNX-2401
    • Combination Therapies
  • Diseases
    • Adult Brain Cancer
    • Pediatric Brain Cancer
  • Clinical Trials
    • Pediatric Clinical Trials
    • Adult Clinical Trials
    • Compassionate Use
  • Company
    • Management Team
    • Board of Directors
    • Key Advisors
    • Clinical Partners
  • Investor Resources
    • Company News & Presentations
    • Scientific Publications
    • Investor Presentations
  • Contact

Clinical Trials Updates

Thought Leadership

DNX-2401 Demonstrates “Dramatic” Survival Benefit in Glioma

Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with…

Read more

Re-engineered Cold Virus Increases Brain Cancer Patients’ Survival, Phase 1 Trial Shows

Re-engineering a common cold virus to attack the deadliest kind of brain tumor extended the…

Read more

Early Trial Shows ‘Smart Bomb’ Virus Extends Survival in Patients With Glioblastoma

Findings from an early phase clinical trial that used a so-called “smart bomb” virus —…

Read more

The Deadly Viruses Being Used To Combat Incurable Cancers

Zika, polio and adenovirus are hardly the first trio that comes to mind when considering…

Read more

Treating diffuse midline gliomas with an oncolytic virus

Results from a phase 1 clinical trial of the oncolytic virus DNX-2401, report successful intratumoral…

Read more

The Common Cold as Cure?

As the nation mourns U.S. Sen. John McCain, TMC News is reposting this month’s story about a…

Read more

Convergence of technology, immunotherapy and courage help U of M patient rise above life-threatening brain tumor

In May 2018, 29-year-old Burnsville, MN, resident, Adam Donahue, began experiencing unusual symptoms. “I had…

Read more
< 1 2 3

Clinical Trials Updates

CPRIT Provides $10.8M Grant to Advance B...

September 22, 2025

The oncolytic virus Delta-24-RGD elicits...

June 13, 2025

Oncolytic Adenovirus and Tumor-Targeting...

June 13, 2025

Localized Treatment with Oncolytic Adeno...

June 13, 2025

Preclinical Characterization of the Anti...

June 13, 2025

Examination of the Therapeutic Potential...

June 13, 2025

See More Content
footer-logo
  • Address

    3400 Edloe Street, Suite 335 Houston, TX 77027

Therapies
  • DNX-2401 (tasadenoturev)
  • Combination Therapies
Diseases
  • Adult Brain Cancer
  • Pediatric Brain Cancer
Science
  • Pediatric Clinical Trials
  • Adult Clinical Trials
Company
  • Management Team
  • Board of Directors
  • Clinical Partners
Contact
  • Terms of Use Policy
  • Privacy Policy

Copyright © 2026. CVBio. All Rights Reserved